HCPLive Network

Fred Poordad, MD, on Ethnic Differences in Telaprevir Treatment Effect

In this video Fred Poordad, MD, Chief of Hepatology and Liver Transplantation at the Comprehensive Transplant Center at Cedars-Sinai Medical Center evaluates the effect of race on the response to treatment and viral resistance profiles with telaprevir combination therapy.


Related Videos
In this video, Ira Jacobson, MD, chief of the division of gastroenterology and hepatology at Weill Medical College of Cornell University, discusses the new standard of care for hepatitis C patients: triple therapy including one of the recently approved protease inhibitors (telaprevir or boceprevir) along with pegylated interferon and ribavirin.
In this video, Paul Kwo, MD, FACG, professor of medicine in the division of gastroenterology and hepatology at the Indiana University School of Medicine, discusses a program in which hepatitis C screening was offered to patients aged 50 to 65 during routine colonoscopy.
In this video Dr. Alexander talks about investigators found that infections across the board were reduced when they implemented strategies specifically targeting a reduction in MRSA infections